Raija Auvinen

Raija Auvinen

Auto-generated profile, based on publicly available information

Raija Auvinen

Inflammation Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2020 in Infectious Diseases
Verified
Journal Article
Open access
RARaija Auvinen
Raija Auvinen
HNHanna Nohynek
Hanna Nohynek
RSRitva Syrjänen
Ritva Syrjänen
JOJukka Ollgren
Jukka Ollgren
TKTuija Kerttula
Tuija Kerttula
KSKirsi Skogberg
Kirsi Skogberg
We compared the clinical characteristics, findings, and outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) or influenza to detect relevant differences. From December 2019 to...

3 October 2021 in Influenza and Other Respiratory Viruses
Verified
Journal Article
Open access
PDF file
RARaija Auvinen
Raija Auvinen
RSRitva Syrjänen
Ritva Syrjänen
JOJukka Ollgren
Jukka Ollgren
HNHanna Nohynek
Hanna Nohynek
KSKirsi Skogberg
Kirsi Skogberg
Background: The clinical significance of respiratory syncytial virus (RSV) among adults remains underinvestigated. We compared the characteristics and population‐based attack rates of RSV and influenza hospitalizations.Methods: During 2018–2020, we recruited hospitalized adults with respiratory infection to our prospective substudy at a tertiary care hospital in Finland and compared the characteristics of RSV and influenza patients. In our retrospective substudy, we calculated the attack rates of all RSV and influenza hospitalizations among adults in the same geographic area during 2016–2020.Results: Of the 537 prospective substudy patients, 31 (6%) had RSV, and 106 (20%) had influenza. Duration of hospitalization, need for intensive care or outcome did not differ significantly between RSV and influenza patients. RSV was more often missed or its diagnosis omitted from medical record (13% vs 1% p = 0.016 and 48% vs 15%, p > 0.001). In the retrospective substudy, the mean attack rates of RSV, influenza A, and influenza B hospitalizations rose with age from 4.1 (range by season 1.9–5.9), 15.4 (12.3–23.3), and 4.7 (0.5–16.2) per 100,000 persons among 18‐ to 64‐year‐olds to 58.3 (19.3–117.6), 204.1 (31.0–345.0), and 60.4 (0.0–231.0) per 100,000 persons among 65+‐year‐olds and varied considerably between seasons.Discussion: While the attack rates of influenza hospitalizations were higher compared with RSV, RSV and influenza hospitalizations were similar in severity. Missing or underreporting of RSV infections may lead to underestimating its disease burden. Both RSV and influenza caused a substantial amount of hospitalizations among the elderly, stressing the need for more effective interventions.

29 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RARaija Auvinen
Raija Auvinen
HNHanna Maria Nohynek
Hanna Maria Nohynek
RSRitva Syrjänen
Ritva Syrjänen
JOJukka Ollgren
Jukka Ollgren
TKTuija Kerttula
Tuija Kerttula
KSKirsi Skogberg
Kirsi Skogberg
Objective: We compared the clinical characteristics, findings and outcomes of hospitalized patients with coronavirus disease 2019 (COVID-19) or influenza to detect relevant differences. Methods: From December 2019 to April 2020, we recruited all eligible hospitalized adults with respiratory infection to a prospective observational study at the HUS Jorvi Hospital, Finland. Influenza and SARS-CoV-2 infections were confirmed by RT-PCR. Follow-up lasted for at least 30 days from admission. Results: We included 61 patients, of whom 28 were COVID-19 and 33 influenza patients with median ages of 53 and 56 years. Majority of both COVID-19 and influenza patients were men (61% vs 67%) and had at least one comorbidity (68% vs 85%). Pulmonary diseases and current smoking were less common among COVID-19 than influenza patients (5 [18%] vs 15 [45%], P=0.03 and 1 [4%] vs 10 [30%], P=0.008). In chest x-ray at admission, ground-glass opacities and consolidations were more frequent among COVID-19 than influenza patients (19 [68%] and 7 [21%], P < 0.001). Severe disease and intensive care unit (ICU) admission occurred more often among COVID-19 than influenza patients (26 [93%] vs 19 [58%], P=0.003 and 8 [29%] vs 2 [6%], P=0.034). COVID-19 patients were hospitalized longer than influenza patients (6 days [IQR 4-21] vs 3 [2-4], P<0.001). Conclusion: Bilateral ground-glass opacities and consolidations in chest X-ray may help to differentiate COVID-19 from influenza. Hospitalized COVID-19 patients had more severe disease, required longer hospitalization and were admitted to ICU more often than influenza patients, which has important implications for public health policies.

26 December 2024 in Infection Prevention in Practice
Verified
Journal Article
Open access
RARaija Auvinen
Raija Auvinen
KHKaisa Huotari
Kaisa Huotari
HNHanna Nohynek
Hanna Nohynek
RSRitva K. Syrjänen
Ritva K. Syrjänen
KSKirsi Skogberg
Kirsi Skogberg
While nosocomial influenza is common, the risk of transmission in acute care remains unclear in the absence of systematic surveillance. Even less is known about the risk of nosocomial respiratory syncytial virus (RSV) among immunocompetent adults. To compare the proportions and incidences of nosocomial cases caused by these two similar respiratory infections among hospitalized adults. A retrospective study was conducted at two tertiary care hospitals in Southern Finland. Data on all hospitalized adult patients with a positive RSV or influenza test during 2016–22 were used to detect all nosocomial and community-acquired RSV and influenza cases. The proportion of nosocomial cases of all hospitalized cases was calculated. The incidences of nosocomial cases per 1000 bed-days were calculated by season and ward type for the five seasons before the COVID-19 pandemic. Nosocomial RSV and influenza occurred in 2.8% and 8.1% of all hospitalized adult patients with a laboratory-confirmed infection. Over five seasons, 2016–20, the total incidences of nosocomial RSV and influenza cases per 1000 bed-days were 0.027 (95% confidence interval: 0.013, 0.050) and 0.32 (0.27, 0.39). Nosocomial RSV infections were especially poorly recorded with a virus-specific ICD-10 diagnosis code listed for only 16.7% of RSV and 59.8% of nosocomial influenza patients. Despite preventive measures, the incidence of nosocomial influenza was more than tenfold, and the proportion of nosocomial cases was almost threefold compared with RSV among hospitalized adults in acute care. Prevention and surveillance of both nosocomial influenza and RSV should be improved also among immunocompetent adult patients.

1 December 2024 in Clinical Epidemiology
Verified
Journal Article
Open access
TNTuomo Nieminen
Tuomo Nieminen
APArto Palmu
Arto Palmu
RARaija Auvinen
Raija Auvinen
SKSangita Kulathinal
Sangita Kulathinal
KAKari Auranen
Kari Auranen
JJJukka Jokinen
Jukka Jokinen
Purpose: We developed a hybrid safety surveillance approach for a large, pragmatic clinical trial of a high-dose quadrivalent influenza vaccine (QIV-HD), using both active and passive data collection methods. Here, we present the methods and results for the passive register-based surveillance of serious adverse events (SAEs), which replaced conventional SAE reporting during the trial. Patients and Methods: The trial recruited over 33,000 older adults of whom 50% received the QIV-HD while the rest received a standard-dose vaccine (QIV-SD) as a control vaccine. We collected diagnoses related to all acute hospitalizations during the six months following vaccination from national registers. During the blinded phase of the trial, we utilized a cohort study design and compared the incidences of 1811 ICD10 diagnosis groups (SAE categories) between the trial population and older adults vaccinated with the QIV-SD outside the trial, either during the study or the previous influenza season. Based on a real-time probabilistic comparison, we flagged SAE categories with higher incidence in the trial population and then evaluated possible causal associations between each flagged category and the trial intervention. Results: Our novel approach to safety surveillance provided information, which we could evaluate in real-time during the trial. The trial participants experienced 1217 hospitalizations related to any SAE categories, contributed by 941 patients. We flagged 10 SAE categories for further analysis during the study but based on further data review, none presented strong evidence of causality with vaccination. Conclusion: Safety signals can be detected and evaluated in real-time during a pragmatic vaccine trial with register-based follow-up, utilizing passive data collection and population level comparison. Compared to conventional methods of safety follow-up, this method is likely to be more comprehensive, objective and resource effective.